## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Michel J. N. CORMIER, et al.

Serial Number: 10/608.304

Filing Date: June 27, 2003

Title: TRANSDERMAL DRUG DELIVERY DEVICES HAVING COATED MICROPROTRUSIONS Group Art Unit: 1616

Examiner: James Henry Alstrum Acevedo

CONFIRMATION NO: 8982

FILED ELECTRONICALLY ON: May 16, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

١.	37 CF. because:	R §1.9	17(b). This Information Disclosure Statement should be considered by the Office		
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under $\$1.53(d)$ ;		
			OR		
		(2)	It is being filed within 3 months of entry of the national stage as set forth in $\S1.491$ in an international application;		
			OR		
		(3)	It is being filed before the mailing of a first Office action on the merits;		
			OR		
	$\boxtimes$	(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.		
3.	.   37 CFR §1.97(c). Although this Information Disclosure Statement is being filed after the perio specified in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a find office action under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwis closes prosecution on the merits, this Information Disclosure Statement should be considered because it is accompanied by one of:				
		a stat	ement as specified in §1.97(e) provided concurrently herewith;		
			OR		
			of \$180.00 as set forth in $\$1.17(p)$ authorized below, enclosed, or included with the tent of other papers filed together with this statement.		
С.	date of the	earlie	7(d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, efore payment of the issue fee and should be considered because it is accompanied		
		i. a	statement as specified in §1.97(e);		
			AND		
			fee of \$180.00 as set forth in $\$1.17(p)$ is authorized below, enclosed, or included ith the payment of other papers filed together with this Statement.		
Э.	☐ 37 CFI	R §1.9	7(e). Statement.		
		A sta	tement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);		
			AND/OR		
		A sta	tement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);		
			AND/OR		
		infor	py of a dated communication from a foreign patent office clearly showing that the mation disclosure statement is being submitted within 3 months of the filing date on ommunication is provided in lieu of a statement under 37 C.F.R. $\S$ 1.97(e)(1) as ded for under MPEP 609.04(b) V.		
€.	disclosure application	statem that v	uder 37 C.F.R. §1.704(d). Each item of information contained in the information ent were first cited in a communication from a foreign patent office in a counterpart was received by an individual designated in § 1.56(c) not more than thirty (30) days g of this information disclosure statement. This statement is made pursuant to the		

	requirements of 37 C.F.R. $\S1.704(d)$ to avoid reduction of the period of adjustment of the patent tenfor Applicant(s) delay.				
F. \( \times 37 CFR \)\( \)\( \)\( \)\( \)\( \)\( \)\( \)\					
		Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.			
		OR			
	$\boxtimes$	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.			
		AND/OR			
	$\boxtimes$	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR $\S1.98$ (a)(2).			
		AND/OR			
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR $\S1.98(a)(2)(iii)$ .			
G.	37 CF. references.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or			
		Pursuant to 37 CFR $\S1.98(a)(3)(i)$ , a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.			
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.			
		OR			
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:			
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.			
H.	37 CF	R §1.98(d). Copies of patents, publications and pending U.S. patent applications, or other a specified in 37 C.F.R. § 1.98(a) are not provided herewith because:			
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.			
		Application in which the information was submitted:			
		Information Disclosure Statement(s) filed on:			
		AND			
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (e) of 37 CFR $\S$ 1.98.			

I. \(\infty\) Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.33392-714.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Samir Elamrani, Reg. No. 43,601

Dated: May 19

650 Page Mill Road Palo Alto, CA 94304-1050

(650) 493-9300 Customer No. 066956

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/608,304	
STATEMENT BY APPLICANT				Filing Date	June 27, 2003	
				First Named Inventor	Michel J. N. Cormier	
				Art Unit	1616	
				Examiner Name	James Henry Alstrum Acevedo	
Sheet	1	Of	1	Attorney Docket Number	33392-714.201	

		U.S.	PATENT DO	CUMENTS	
Examiner Initials*	No.	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figure Appear
	1.	US 2002/0087182	07/04/2002	Trautman et al.	
	2.	US 2002/0128599	09/12/2002	Cormier et al.	
	3.	US 2002/0177839	11/28/2002	Cormier et al.	
	4.	US 2003/0181936	09/25/2003	Trautman et al.	
	5.	US 2003/0199810	10/23/2003	Trautman et al.	
	6.	US 6,230,051	05/08/2001	Cormier et al.	
	7.	US 6,322,808	11/27/2001	Trautman et al.	
	8.	US 6,855,131	02/15/2005	Trautman et al.	
	9.	US 6,918,901	07/19/2005	Theeuwes et al	
	10.	US 6,953,589	10/11/2005	Trautman et al.	
	11.	US 7,131,960	11/07/2006	Trautman et al.	
	12.	US 7,184,826	02/27/2007	Cormier et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>1</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	13.	WO 93/17754	09/16/1993	Gross et al.		
	14.	WO 96/37256	11/28/1996	Godshall		

Examiner Date		
	Examiner	
Signature Considered	Cimmotorno	cure Considered

Expansion | Continuous | Contin

check mick here if Beglin language Translation is statistical.

The solutions of information is required by TOTE 1.97 at 1.95. The information is required to obtain or retain a bound by the sixth is as fifte (and by the USPTD to process) as explication. Confidentially is government. O'TE 1.97 at 1.97 at 1.95 at 1.95